In studies on Wistar white rats of different ages with various experimental models of cerebral ischemia (intracerebral hemorrhage, carotid artery occlusion, prenatal hypoxia), it was found that pharmacotherapy of emerging mitochondrial disorders with modulators of 70 kilodalton heat shock proteins (HSP70) expression - Cerebrocurin (composition: neuropeptides, S-100 proteins, reelin, factor nerve growth (NGF) ), Glutoredoxin, Tamoxifen, (S)-2,6-diaminohexanoic acid, 3-methyl-1,2,4-triazolyl-5-thioacetate significantly (p<0.05) stimulates energy production brain. This is expressed in an increase in the content of a number of intermediates of energy metabolism (glucose, pyruvate, succinate, isocitrate, malate) in the brain tissue, as well as an increase in the activity of pentose phosphate shunt dehydrogenase. A significant (p<0.05) decrease in the level of lactic acid in the brain indicates a decrease in the proportion of anaerobic glycolysis. The most pronounced energotropic effect was shown by cerebrocurin (150 µl/kg) and (S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate (50 mg/kg). On the 21st day of treatment of rats with cerebral ischemia, there is a gradual disappearance of severity between animals with simulated pathology and healthy rats, which is associated with actively recovering mitochondrial energy production and cerebral load in general. These changes in energy metabolism correlate with the normalization of oxidant-antioxidant balance and the concentration of HSP70 and HSF-1a in the cytosol and mitochondria of the cerebral ischemia zone and are manifested in a significant (p<0.05) decrease in ultrastructural disorders of mitochondria. The energy-tropic and mitoprotective effects of the studied drugs are associated with their ability to protect mitochondrial proteins from oxidative damage by increasing the concentration of HSP70, prolong the lifespan of HSF-1a, and activate alternative energy generation pathways.